Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) covers the month of February 2024, with a specific transaction date of February 21, 2024. The document serves as a transaction notification regarding dealings in the company's Ordinary Shares by a Person Discharging Managerial Responsibilities (PDMR) and a person closely associated with them (PCA).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
- Instrument: Ordinary Shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Volume: 8,772 shares.
- Transaction Price: £0.00 (Nil consideration).
- Transaction Type: Transfer between spouses.
Material Changes
The filing reports a change in beneficial ownership resulting from a private transfer. Victoria Whyte (Company Secretary) transferred 8,772 Ordinary Shares to her spouse, Iain Whyte (PCA), for nil consideration. There are no material changes to the company's operations or financial position reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share transfer.
Key Facts for Investor Verification
- Verify the identity of the PDMR (Victoria Whyte, Company Secretary) and the PCA (Iain Whyte).
- Confirm the transaction date of February 21, 2024.
- Note that the transaction involved 8,772 shares transferred for nil consideration, indicating a non-market, private family transfer rather than a sale or purchase on the open market.
- Understand that this filing contains no financial results or strategic updates for GSK plc.